A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)

This analysis compared quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) between nivolumab and everolimus among previously treated patients with advanced renal cell carcinoma enrolled in the phase III CheckMate 025 trial (NCT01668784). At 45-month follow-up, overall...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical genitourinary cancer 2019-10, Vol.17 (5), p.356-365.e1
Hauptverfasser:	Shah, Ruchitbhai, Botteman, Marc, Solem, Caitlyn T., Luo, Linlin, Doan, Justin, Cella, David, Motzer, Robert J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Renal Cell - diagnosis Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology CheckMate 025 Disease-Free Survival Everolimus - administration & dosage Everolimus - adverse effects Female Follow-Up Studies Humans Immunotherapy Kidney cancer Kidney Neoplasms - diagnosis Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Male Middle Aged Nivolumab - administration & dosage Nivolumab - adverse effects Prognosis Quality-Adjusted Life Years Quality-adjusted survival Risk-benefit Surveys and Questionnaires Survival Rate Symptom Assessment - methods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!